ClinicalTrials.gg
Not yet recruitingNCT05687448DIAMONDUpdated Jun 12, 2025

DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

A Phase 3 interventional study of Apixaban 5 MG Oral Tablet and Aspirin 75 to 100mg once a day in Aortic Valve Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Aortic Valve Disease with a site in France — 5 open to participants now, 5 under way, 1 of them phase 3. Aortic Valve Disease · France.

Planned enrollment
Largest of 11
1,500 · median 658
Started
2025
the only one that year
Phase 3
Only one
of the 26
Registered
23rd of 26
by date
Lead sponsor
2 of 26
Assistance Publique - Hôpitaux de Paris

Among the 26 studies in Aortic Valve Disease with a site in France, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 3, and was the 23rd registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

5 of the 26 studies in Aortic Valve Disease with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Aortic Valve Disease with a site in France, or all of them as a file.
02

Study summary

DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with aortic bioprosthesis (excluding TAVI) at least 7 days after cardiac surgery.

Experimental group:

Patients treated with apixaban 5 mg twice daily (BID)

Active Comparator group:

Aspirin 75 to 100mg once a day

The primary objective is to demonstrate that antithrombotic treatment with apixaban is superior to aspirin in patients with recent surgical bioprosthetic aortic valve replacement for the primary composite efficacy endpoint of death from any cause, myocardial infarction, stroke, systemic embolism, deep vein thrombosis, or pulmonary embolism and valve thrombosis after 105 days of follow-up.

Read the detailed description

Early antithrombotic management of patients who have undergone aortic valve replacement using a bioprosthesis remains a source of medical concern. The optimal antithrombotic strategy early after surgery remains controversial due to lack of high-quality evidence. Some observational studies support the use of vitamin K antagonists (VKAs) compared to aspirin (ASA) to significantly reduce the risk of thromboembolism but suffer from major source of bias inherent to retrospective analyses of observational data. A small, randomized trial found that VKA for 3 months significantly increased major bleeding compared with ASA, without reducing the rate of deaths or thromboembolic events but this study was underpowered for ischemic events. There is therefore a lack of evidence demonstrating the superiority of anticoagulant treatment compared to aspirin early after bioprosthetic aortic valve surgery. Current ESC guidelines recommend that ASA or VKA should be considered for 3 months after surgical implantation of an aortic bioprosthesis. At the opposite, current AHA/ACC guidelines recommend that anticoagulation with VKA to achieve an INR of 2.5 is reasonable for at least 3 months and for as long as 6 months for patients at low risk of bleeding (IIa, level B). However, anticoagulation by VKAs is currently underused and guideline recommendations are not followed by most clinicians as VKAs have major drawbacks: narrow therapeutic window, variable dose-response in individuals, interaction with several foods and drugs.

Despite their superiority to reduce bleeding in patients with non-valvular atrial fibrillation compared to VKAs, direct oral anticoagulants (DOACs) including apixaban have not been well evaluated in the first 3 months after surgical bioprosthetic valve implantation. A small, randomized trial found that edoxaban was non-inferior to warfarin for preventing thromboembolism and the occurrence of major bleeding in the first 3 months after aortic or mitral surgical bioprosthetic valve implantation. DOAC(s) are effective in patients with atrial fibrillation and bioprosthetic valve implanted after 3 months.

Finally, there is an unmet clinical need for an alternative to ASA or VKAs, such as an anti-Xa DOAC like apixaban, as anticoagulation in patients in the first 3 months after surgical bioprosthetic valve implantation.

The purpose of this study is to compare the efficacy of apixaban and aspirin on ischemic endpoints during the first 3 months after aortic surgical bioprosthetic valve implantation excluding TAVI.

03

Conditions studied

  • Aortic Valve Disease

Keywords

  • Anticoagulant
  • Aortic valve
  • Apixaban
  • Aspirin
  • Stroke
  • Hemorrhage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age
  2. Prior implantation of a surgical bioprosthesis in the aortic position at least 7 days and before hospital discharge (excluding TAVI)
  3. Participants currently not requiring chronic anticoagulation for another reason (atrial fibrillation, pulmonary embolism or any other condition)
  4. Patients affiliated to social security
  5. Patient able to give free, informed and written consent

Exclusion criteria

Exclusion Criteria:

  1. Any cardiac surgery less than 7 days prior to enrollment or more than 1 month
  2. Mechanical valve in any position or combined valve surgery (mitral or tricuspid).
  3. Any major bleeding in the three months (90 days) prior to enrollment.
  4. Active bleeding or high risk of bleeding after cardiac surgery (i.e. hemopericardium) or lesion or condition considered as a significant risk factor for major bleeding according to investigator
  5. Atrial fibrillation requiring chronic anticoagulation
  6. Need to be on dual antiplatelet therapy (aspirin >100 mg daily and a P2Y12 inhibitor, i.e. clopidogrel, ticagrelor, prasugrel) or requiring chronic anticoagulation whatever the treatment (oral or injection).
  7. Known or other to apixaban (hepatic disease associated with coagulopathy and bleeding risk).
  8. \<40 mL/min (Cockcroft) or patients requiring apixaban dose reduction.
  9. Known hypersensitivity or other contraindications to aspirin (Hypersensitivity to aspirin or any of the , history of asthma induced by the administration of salicylates, ongoing peptic ulcer, constitutional or acquired hemorrhagic disease including gastrointestinal bleeding, history of hemorrhagic stroke and thrombocytopenia, pregnancy after 24 weeks of gestation, risk of bleeding, severe renal failure, severe hepatic impairment, uncontrolled severe heart failure
  10. Known hypersensitivity or other contraindications to heparin or low molecular weight heparin (history of heparin-induced thrombocytopenia, hypersensitivity to any of the excipients...)
  11. Ischemic stroke within 1 month or intracranial hemorrhage
  12. Active endocarditis at the time of screening for enrollment.
  13. Women of without efficient , pregnant or breastfeeding women.
  14. Concomitant combined strong P-gp and inducers or inhibitors.
  15. History of non-compliance
  16. Participation in another interventional study
  17. Active cancer or less than 1 year
  18. Persons deprived of their liberty by judicial or administrative decision
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Patients treated with apixaban 5 mg twice daily (BID)

    Drug: Apixaban 5 MG Oral Tablet

  • Active comparator
    Active Comparator group:

    Patients treated with Aspirin 75 to 100mg once a day

    Drug: Aspirin 75 to 100mg once a day

Interventions

  • DrugApixabanStudies of ApixabanApixaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients treated with apixaban 5 mg twice daily (BID)

    Also known as: Experimental Group

  • DrugAspirin 75 to 100mg once a day

    Patients treated with Aspirin 75 to 100mg once a day

    Also known as: Active Comparator

06

What researchers measure

Primary outcomes

  1. Major Adverse Clinical Events (MACE)

    The primary endpoint is a composite efficacy endpoint including death from any cause, myocardial infarction, stroke, systemic embolism, deep vein thrombosis, or pulmonary embolism and valve thrombosis.

    Time frame: Up to 3.5 months

Secondary outcomes

  1. Bleeding

    ISTH major and non-major clinically relevant bleeding

    Time frame: Up to 3.5 months

  2. Death

    Including cardiovascular and non cardiovascular death

    Time frame: Up to 3.5 months

  3. Myocardial infarction

    Time frame: Up to 3.5 months

  4. Stroke

    Time frame: Up to 3.5 months

  5. Systemic embolism

    Time frame: Up to 3.5 months

  6. Deep vein thrombosis or pulmonary embolism

    Time frame: Up to 3.5 months

  7. Valve thrombosis

    Time frame: Up to 3.5 months

  8. Bleeding

    According to ISTH major and non-major clinically relevant bleeding, BARC and TIMI 6, BARC and TIMI Classifications

    Time frame: Up to 3.5 months

  9. Echographic parameter of aortic valve

    Variation of mean aortic gradient (mm/Hg)

    Time frame: Up to 3.5 months

  10. Assessment of coagulation

    Measured by thrombin generation in a subgroup population (n=216)

    Time frame: Up to 3.5 months

  11. To evaluate platelet activation (sP-selectin) in a subgroup population (n = 216)

    Time frame: Up to 3.5 months

  12. To build a population PK/PD in the experimental group

    Measuring the apixaban concentration (anti-Xa activity expressed in ng/mL) (apixaban, n = 108)

    Time frame: Up to 3.5 months

07

Study locations

1 site
  • Service de Cardiologie Hôpital Lariboisière
    Paris, 75010, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2025, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Jan 18, 2023
StartEst.
Sep 2025
Primary completionEst.
Sep 2025
CompletionEst.
Mar 2029
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05687448
Responsible party
Sponsor
First posted
Jan 18, 2023
Start date
Sep 2025 (estimated)
Primary completion
Sep 2025 (estimated)
Completion
Mar 2029 (estimated)
Last update
Jun 12, 2025

Study contacts

Jean-Guillaume DILLINGER, Professor
Contact
jean-guillaume.dillinger@aphp.fr
+33 1 49 95 86 74
Bernard IUNG, Professor
Contact
bernard.iung@aphp.fr
+33 1 40 25 66 01
Jean-Guillaume DILLINGER, Professor
principal investigator · Assistance Publique Hôpitaux Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion